entertainment -WSS

entertainment

author：entertainment 2025-10-02 20:49:06 - browse：57

Two people run on the sugar-phosphate backbone of DNA while holding base pairs — in the lab coverage from STAT — Adobe

LONDON — Widespread genetic testing as well as the development of cutting-edge, customized genetic therapies have opened the door to treating many more inherited conditions than previously possible. A few recent cases, in which bespoke medicines were created for children with exceedingly rare mutations, have raised hopes for furthering the approach.

Now, researchers and government agencies in the U.K. are trying to figure out the nitty-gritty to replicate those early one-off successes for as many patients as possible — what sort of preclinical testing a tailor-made treatment needs to go through before being used, what regulatory thresholds each treatment needs to clear, and how to pay for these therapies.

“A lot of the barriers are no longer scientific — we can make these drugs,” said Matthew Wood, a professor of pediatrics at the University of Oxford. “It’s more about, can we make them at a cost that is reasonable enough? And can we get the regulators to reduce the barriers to doing this so that when a patient shows up, you can actually make a drug quickly enough to benefit that patient, rather than it costing huge amounts of money and taking two or three years to do it?”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Readout LOUD podcast, live from the STAT Breakthrough Summit East

explore

WSS

'Patient friction coefficient' can gauge a clinical trial's patient burden

Think you might have Covid

The tragedy of Johnson & Johnson’s Covid vaccine

FDA clears AI tool for detecting skin cancer

Mirador, a new biotech startup, launches with $400 million

U.K. officials, researchers try to ease path for bespoke genetic treatments

hotspot

entertainment

leisure time

The cancer drug shortage isn’t new — and neither are the solutions

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

Drug repurposing or repositioning? The language matters

Parkinson’s finding may lead to tests and, someday, treatments

Dobbs anniversary: the lost opportunity of abortion as health care

Test for long Covid? Researchers find new clue in blood samples

Wildfire smoke exposes gaps in outdoor worker protections

Testing GLP

United colonoscopy coverage change 'may cost lives,' doctors say

Biotech venture capitalists face new demands from investors

leisure time

Humana cuts profit projections as Medicare Advantage costs soar

Asbestos ban is immediate, but health effects will linger for decades

Steward Health Care expansion into Malta flopped

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Cancer, immunology, HIV research ensnared in fetal tissue politics

Medicare Advantage today, explained in one chart

knowledge

explore

hotspot

knowledge